Cholesterol-rich nanoemulsions (LDE) for drug targeting of cholesteryl-succinyl- 5-fluorouracil conjugate

Current Nanoscience

Volumn 10, Issue 2, 2014, Pages 287-291

  Alanazi, Fars K ^a   Haq, Nazrul ^a,b   Radwan, Awwad A ^a   Alsarra, Ibrahim A ^a,b   Shakeel, Faiyaz ^a,b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Cholesterol rich nanoemulsion; Cholesteryl succinyl 5 fluorouracil; Droplet size; Drug release; Surface morphology

Indexed keywords

CHOLESTEROL; DIALYSIS MEMBRANES; DROPS; EMULSIFICATION; OPTIMIZATION; SURFACE MORPHOLOGY; ZETA POTENTIAL;

5-FLUOROURACIL; CHOLESTERYL-SUCCINYL-5-FLUOROURACIL; DROPLET SIZES; DRUG RELEASE; NANO-EMULSIONS; NANOEMULSION; POLYDISPERSITY INDICES; THERAPEUTIC EFFICACY;

REFRACTIVE INDEX;

CHOLESTEROL; CHOLESTERYL SUCCINYL 5 FLUOROURACIL; FLUOROURACIL DERIVATIVE; PHOSPHATIDYLCHOLINE; POLYSORBATE 20; POLYSORBATE 80; TRIOLEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; DIALYSIS MEMBRANE; DRUG CONJUGATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG TARGETING; IN VITRO STUDY; NANOEMULSION; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REFRACTION INDEX; SURFACE PROPERTY; SUSTAINED DRUG RELEASE; VISCOSITY; ZETA POTENTIAL;

EID: 84897445437     PISSN: 15734137     EISSN: 18756786     Source Type: Journal    
DOI: 10.2174/15734137113096660119     Document Type: Article

References (31)

1. Li, X.M.; Xu, Y.L.; Chen, G.G.; Wei, P.; Ping, Q. PLGA nanoparticles for the oral delivery of 5-fluorouracil using high pressure homogenizationemulsification as the preparation method and in vitro/in vivo studies. Drug Dev. Ind. Pharm., 2008, 34(1), 107-115.
2. Dong, Z.; Zheng, W.; Xu, Z.; Yin, Z. Improved stability and tumor targeting of 5-fluorouracil by conjugation with hyaluronan. J. Appl. Polym. Sci., 2013, 130(2), 927-932.
3. Presant, C.A.; Jacobson, J.; Wolf, W.; Waluch, V.; Weitz, I.C.; Macdonald, J.S. Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil? A Southwest oncology group study. Invest. New Drugs, 2002, 20(4), 369-376.
4. Longley, D.B.; Harkin, D.P.; Johnston, P.G. Reviews and comments from the nature publishing group. Nat. Rev. Cancer, 2003, 3, 330.
5. Koukourakis, G.V.; Kouloulias, V.; Koukourakis, M.J.; Zacharias, G.A.; Zabatis, H.; Kouvaris, J. Efficacy of the oral fluorouracil prodrug capecitabine in cancer treatment: a review. Molecules, 2008, 13(8), 1897-1922.
6. Kuzuhara, S.; Ohkoshi, N.; Kanemaru, K.; Hashimoto, H.; Nakanishi, T.; Toyokura, Y.J. Subacute leucoencephalopathy induced by carmofur, a 5ffluorouracil derivative. J. Neurol., 1987, 234(6), 365-370.
7. Casado, E.; Pfeiffer, P.; Feliu, J.; Gonzalez-Baron, M.; Vestermark, L.; Jensen, H.A. UFT (tegafur uracil) in rectal cancer. Ann. Oncol., 2008, 19(8), 1371-1378.
8. Wang, M.; Yuan, Y.; Gao, Y.; Ma, H.M.; Xu, H.T.; Zhang, X.N.; Pan, W.S. Preparation and characterization of 5-fluorouracil pH-sensitive noisome and its tumor targeted evaluation: in vitro and in vivo. Drug Dev. Ind. Pharm., 2012, 38(9), 1134-1141.
9. Gupta, R.R.; Jain, S.K.; Varshney, M. AOT water-in-oil microemulsions as a potential enhancer in transdermal drug delivery of 5-fluorouracil. Coll. Surf. B., 2005, 41(1), 25-32.
10. Li, S.; Wang, A.; Jiang, W.; Guan, Z. Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles. BMC Cancer, 2008, 8, E103.
11. Lin, Y.; Li, Y.; Ooi, C.P. 5-Fluorouracil encapsulated HA/PLGA composite microspheres for cancer therapy. J. Mater. Sci. Mater. Med., 2012, 23(10), 2453-2460.
12. Ahmad, M.Z.; Akhtar, S.; Anwar, M.; Ahmad, F.J. Assam Bora rice starch based biocompatible mucoadhesive microsphere for targeted delivery of 5-fluorouracil in colorectal cancer. Mol. Pharm., 2012, 9(11), 2986-2994.
13. Ashwanikumar, N.; Kumar, N.A.; Nair, S.A.; Kumar, G.V. Methacrylicbased nanogels for the pH-sensitive delivery of 5-fluorouracil in the colon. Int. J. Nanomed., 2012, 7, 5769-5779.
14. Shishu, Kamalpreet, Maheshwari, M. Development and evaluation of novel microemulsion based oral formulations of 5-fluorouracil using non-everted rat intestine sac model. Drug Dev. Ind. Pharm., 2012, 38(3), 294-300.
15. Thomas, A.M.; Kapanen, A.I.; Hare, J.I.; Ramsay, E.; Edwards, K.; Karlsson, G.; Bally, M.B. Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation design, pharmacokinetics and efficacy. J. Control Release, 2011, 150(2), 212-219.
16. Yanyu, X.; Fang, L.; Qineng, P.; Hao, C. The influence of the structure and the composition of water/AOT-Tween 85/IPM microemulsion system on transdermal delivery of 5-fluorouracil. Drug Dev. Ind. Pharm., 2012, 38(12), 1521-1529.
17. Rohit, B.; Pal, K.I. A method to prepare solid lipid nanoparticles with improved entrapment efficiency of hydrophilic drugs. Curr. Nanosci., 2013, 9(2), 211-220.
18. Zhang, Z.; Wo, Y.; Zhang, Y.; Wang, D.; He, R.; Chen, H.; Cui, D. In vitro study of ethosome penetration in human skin and hypertrophic scar tissue. Nanomedicine, 2012, 8, 1026-1033.
19. Valduga, C.J.; Fernandes, D.C.; Lo Prete, A.C.; Azevedo, C.H.M.; Rodrigues, D.G.; Maranhao, R.C. Use of a cholesterol-rich microemulsion that binds to low-density lipoprotein receptors as vehicle for etoposide. J. Pharm. Pharmacol., 2003, 55(12), 1615-1622.
20. Moura, J.A.; Valduga, C.J.; Tavares, E.R.; Kretzer, I.F.; Maria, D.A.; Maranhão, R.C. Novel formulation of a methotrexate derivative with a lipid nanoemulsion. Int. J. Nanomed., 2011, 6, 2285-2265.
21. Maranhão, R.C.; César, T.B.; Pedroso-Mariani, S.R.; Hirata, M.H.; Mesquita, C.H. Metabolic behavior in rats of a non-protein microemulsion resembling low density lipoprotein. Lipids, 1993, 28(8), 691-696.
22. Ades, A.; Carvalho, J.P.; Graziani, S.R.; Amancio, R.F.; Souen, J.S.; Pinotti, J.A.; Maranhao, R.C. Uptake of a cholesterol rich emulsion by neoplastic ovarian tissues. Gynecol. Oncol., 2001, 82(1), 84-87.
23. Graziani, S.R.; Igreja, F.A.F.; Hegg, R.; Meneghetti, C.; Brandizzi, L.I.; Barboza, R.; Amancio, R.F.; Pinotti, J.A.; Maranhao, R.C. Uptake of a cholesterol-rich emulsion by breast cancer. Gynecol. Oncol., 2002, 85(3), 493-497.
24. Azevedo, C.H.; Carvalho, J.P.; Valduga, C.J.; Maranhão, R.C. Plasma kinetics and uptake by the tumor of a cholesterol-rich microemulsion (LDE) associated to etoposide oleate in patients with ovarian carcinoma. Gynecol. Oncol., 2005, 97(1), 178-182.
25. Rodrigues, D.G.; Maria, D.A.; Fernandes, D.C.; Valduga, C.J.; Couto, R.D.; Ibanez, O.C.M.; Maranhao, R.C. Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. Cancer Chemother. Pharmacol., 2005, 55(6), 565-576.
26. Dias, M.L.; Carvalho, J.P.; Rodrigues, D.G.; Graziani, S.R.; Maranhão, R.C. Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers. Cancer Chemother. Pharmacol., 2007, 59(1), 105-111.
27. Shakeel, F.; Haq, N.; Alanazi, F.K.; Alsarra, I.A. Impact of mixed nonionic surfactants on self-nanoemulsification efficiency of Sefsol-218 in glibenclamide nanoemulsion. Curr. Nanosci., 2013, 9(6), 723-729.
28. Shakeel, F.; Haq, N.; Ali, M.; Alanazi, F.K.; Alsarra, I.A. Impact of viscosity and refractive index on droplet size and zeta potential of model o/w and w/o nanoemulsion. Curr. Nanosci., 2013, 9(2), 248-252.
29. Shafiq, S.; Shakeel, F.; Talegaonkar, S.; Ahmad, F.J.; Khar, R.K.; Ali, M. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur. J. Pharm. Biopharm., 2007, 66(2), 227-243.
30. Shakeel, F.; Haq, N.; Elbadry, M.; Alanazi, F.K.; Alsarra, I.A. Ultra fine super self-nanoemulsifying drug delivery system enhanced solubility and dissolution of indomethacin. J. Mol. Liq., 2013, 180(C), 89-94.
31. Villar, A.M.; Naveros, B.C.; Campmany, A.C.; Trenchs, M.A.; Rocabert, C.B.; Bellowa, L.H. Design and optimization of self-nanoemulsifying drug delivery systems (SNEDDS) for enhanced dissolution of gemfibrozil. Int. J. Pharm., 2012, 431(1-2), 161-175.